medigraphic.com

2004, Number 3

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2004; 42 (3)

Proinflammatory Cytokines in Soft Tissue Infection in Patients with Diabetes

Hernández CLS, González VF, Fuentes AJL, González BCR, García EGA

Language: Spanish
References: 18
Page: 227-233
PDF size: 85.38 Kb.


ABSTRACT

Introduction: soft tissue infections are one of the chronic complications of type 2 diabetes mellitus, characterized by immunologic alterations, such as impaired phagocytosis and chemotaxis, and altered lymphocyte function with cytokine over-production, which may play a role in the pathoge-nesis of the disease. Objective: our objective was to describe TNFα IL-6, and IL-10 serum levels in diabetic patients with soft tissue infections. Description: our study was comparative and trans-versal. Site: Hospital de Infectología, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, México. Materials and methods: patients with type 2 diabetes mellitus and soft tissue infections were included and classified as having mild, moderate, or severe soft tissue infections. TNFα, IL-6 and IL-10, were determined in serum samples by ELISA and their correlation with severity and mortality was analyzed. Results: thirty nine patients were studied, six with mild, nine with moderate, and 24 with severe infections. Mean type 2 diabetes mellitus evolution time was 8.2 years. Cytokine serum levels were: TNFα, 34.1 ± 9.6 pg/mL, IL-6, 73.7 ± 86 pg/mL, and IL-10 35.7 ± 30.4 pg/mL. In severe infections: TNFα, 36.5 pg/mL; IL-6, 93.3 pg/mL; IL-10, 33.7 pg/mL. In patients who died, TNFα, 37.1 pg/mL (p = 0.05, OR = 2.5, 95 % IC = 0.6 to 10.5); IL-6, 99.6 pg/mL (p = 0.11, OR = 3.2, 95 % CI = 0.8 to 13), and IL-10, 39.3 pg/mL (p = 0.73, OR = 0.97, 95 % CI = 0.21 to 4). Conclusions: there was correlation between IL-6 levels and severity of soft tissue infections. Al-though not statistically significant, a TNFα in-crement was also observed.


REFERENCES

  1. King H. Diabetes and the World Health Organi-zation. Progress towards prevention and control. Diabetes Care 1993;16(1):387-390.

  2. Secretaría de Programación y Presupuesto. Proyec-ciones de población de México de las entidades federativas: 1980-2010. 56-69. México: Secretaría de Programación y Presupuesto; 1990.

  3. González-Villapando C. Epidemiología de la dia-betes mellitus tipo 2 en México. Med Int Mex 1998; 14:S5-S7.

  4. Secretaría de Salud. Boletín Semanal de Epide-miología. Semana 46, 2001. Dirección General de Epidemiología. México: Secretaría de Salud.

  5. Barquera S, Tovar-Guzmán V, Campos-Nonato I, González-Villalpando C, Rivera-Dommarco J. Geography of diabetes mellitus mortality in Me-xico: an epidemiologic transition analysis. Arch Med Res 2003;34(5):407-414.

  6. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286(3):327-334.

  7. Mohanty P, Ghanim H, Hamouda W, Aljada A, Garg R, Dandona P. Both lipid and protein intakes stimulate increased generation of reactive oxygen species by polymorphonuclear leukocytes and mononuclear cells. Am J Clin Nutr 2002;75(4):767-772.

  8. 8. Wong RK, Pettit AI, Quinn PA, Jennings SC, Davies JE, Ng LL. Advanced glycation end products stimulate an enhanced neutrophil respiratory burst mediated through the activation of cytosolic phos-pholipase A2 and generation of arachidonic acid. Circulation 2003;108(15):1858-1864.

  9. 9. Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. Infections in patients with diabetes mellitus. N Engl J Med 1999;341(25):1906-1912.

  10. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 1993 103(2):565-575.

  11. Hack CE, De Groot ER, Felt-Bersma RJ, Nuijens JH, Strack Van Schijndel RJ, Eerenberg-Belmer AJ, et al. Increased plasma levels of interleukin-6 in sepsis. Blood 1989;74(5):1704-1710.

  12. Hessle C, Andersson B, Wold AE. Gram-positive bacteria are potent inducers of monocytic inter-leukin-12 (IL-12) while gram-negative bacteria preferentially stimulate IL-10 production. Infect Immunol 2000;68(6):3581-3586.

  13. Gibbons GW, Habershaw GM. Diabetic foot infections. Anatomy and surgery. Infect Dis Clin North Am 1995;9(1):131-142.

  14. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414(6865):782-787.

  15. Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro-versus antiinflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 2000; 181(1):176-180.

  16. Mandrup-Poulsen T. Diabetes. BMJ 1998;316 (7139): 1221-1225.

  17. Benjafield AV, Glenn CL, Wang XL, Colagiuri S, Morris BJ. TNFRSF1B in genetic predisposition to clinical neuropathy and effect on HDL choles-terol and glycosylated hemoglobin in type 2 dia-betes. Diabetes Care 2001;24(4):753-757.

  18. Hancu N, Netea MG, Baciu I. High glucose con-centrations increase the tumor necrosis factor-alpha production capacity by human peripheral blood mononuclear cells. Rom J Physiol 1998;35 (3-4):325-330.




2020     |     www.medigraphic.com